Pharmaron

Haixin zhihui is an artificial intelligence company. They offer intelligent diagnosis, and treatment systems for tumor diseases have been developed. They provide patients with precise treatment recommendations and assist patients in treatment planning and full disease management.

Shanghai Jiying uses intelligent technology, focusing on data analysis and AI algorithms.

Rxilient Health is a company that specializes in providing contract development and manufacturing organization (CDMO) services for the pharmaceutical industry. It focuses on manufacturing and distributing pharmaceutical products designed to address unmet medical needs as well as health and beauty requirements. The company offers a diverse range of professional dermatology and medical aesthetic products, emphasizing a scientific approach to skin health and aesthetics. This enables Rxilient Health to cater to a wide array of consumer demands in the realm of skincare and cosmetic solutions.

Allergan Biologics developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products.

Imago BioSciences, Inc. is a clinical-stage biotechnology company based in Redwood City, California, founded in 2012. The company specializes in developing novel small molecule therapeutics aimed at treating hematologic diseases, including myelodysplastic syndromes, acute myelogenous leukemia, and other conditions associated with bone marrow failure. Central to its research is the enzyme lysine-specific demethylase 1 (LSD1), which is involved in the regulation of blood cell production. Imago BioSciences is focused on translating advanced scientific insights into transformative therapies that can alter the course of disease, thereby enhancing the quality and longevity of life for patients. Its lead product candidate, Bomedemstat, is an orally administered LSD1 inhibitor currently under evaluation for its potential to modify disease progression in patients with myeloproliferative neoplasms, a group of chronic bone marrow cancers.

Absorption Systems is a research organization that specializes in providing non-clinical contract research organization (CRO) services, primarily focused on predicting human outcomes related to drug absorption, distribution, metabolism, and excretion. Headquartered in Exton, Pennsylvania, with additional locations in San Diego, California, and Panama City, Panama, the company serves a diverse clientele in the pharmaceutical and biotech industries, including both small virtual firms and large pharmaceutical corporations. Absorption Systems emphasizes flexibility and collaboration, allowing it to tailor studies and develop custom models to meet the unique needs of its clients. This approach has fostered innovative partnerships within the industry and with regulatory agencies, enhancing the drug discovery and development process for small and large molecules, as well as cell and gene therapies and medical devices.

Xceleron, founded in 1997 in York, UK, and now headquartered in Germantown, Maryland, specializes in bioanalytical accelerator mass spectrometry (AMS) services for drug development. The company pioneered human microdose and microtracer techniques to assess the pharmacokinetics and metabolism of developmental drugs during Phase 0, Phase I, and Phase II/III clinical trials. By focusing on micro-dosing and pre-clinical evaluations, Xceleron effectively conducts intravenous pharmacokinetics, metabolite profiling, and mass balance investigations in humans. The company's expertise is particularly beneficial given the challenges posed by contemporary small molecules, which often exhibit low solubility and long half-lives, making early pharmacokinetic and metabolic characterization essential for cost-effective clinical advancement. Driven by a commitment to integrity and scientific collaboration, Xceleron aims to facilitate the rapid and affordable delivery of life-changing products to those in need.

Quotient Bioresearch Limited is a prominent contract research organization (CRO) based in Rushden, United Kingdom, specializing in early-stage and specialized drug development services. Founded in 1992, the company caters to clients in the pharmaceutical, biotechnology, agrochemical, chemical, and animal health industries globally. Quotient Bioresearch offers an array of integrated services, including radiochemistry and drug metabolism, with a focus on applications such as tritium and stable isotope synthesis, carbon-14 synthesis, and preclinical drug metabolism and pharmacokinetics (DMPK). The company also provides comprehensive metabolism services, including bioanalysis, drug-drug interaction assessments, and metabolite analysis. Its radiochemistry capabilities encompass 14C and 3H radiolabeling, GMP synthesis, and GLP analysis. Quotient Bioresearch is recognized for its scientific and technical expertise, enabling it to deliver tailored solutions to meet the diverse needs of its clients. As of February 2016, it operates as a subsidiary of Pharmaron, Inc.

Bridge Laboratories, Inc. operates as a preclinical contract research organization. Its drug development and preclinical services include short and long-term in vivo studies ranging from acute to carcinogenicity protocols; and species and routes of administration.